Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
62.2M
-
Number of holders
-
82
-
Total 13F shares, excl. options
-
34M
-
Shares change
-
+10.8M
-
Total reported value, excl. options
-
$601M
-
Value change
-
+$210M
-
Number of buys
-
65
-
Number of sells
-
-29
-
Price
-
$17.66
Significant Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) as of Q2 2020
99 filings reported holding PTGX - Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 as of Q2 2020.
Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) has 82 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34M shares
of 62.2M outstanding shares and own 54.77% of the company stock.
Largest 10 shareholders include FMR LLC (5.17M shares), RTW INVESTMENTS, LP (3.38M shares), FARALLON CAPITAL MANAGEMENT LLC (2.5M shares), Johnson & Johnson Innovation - JJDC, Inc. (2.45M shares), BVF INC/IL (2.37M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.2M shares), BlackRock Inc. (2.04M shares), BAKER BROS. ADVISORS LP (1.91M shares), VANGUARD GROUP INC (1.42M shares), and DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (1.01M shares).
This table shows the top 82 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.